# Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure

> **NCT07131475** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Blast Injury

## Interventions

- **DRUG:** PBR28 TSPO PET

## Key facts

- **NCT ID:** NCT07131475
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131475, "Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07131475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*